Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Formycon AG

Fresenius Kabi specializes in lifesaving medicines and technologies for critically and chronically ill patients and focuses on improving healthcare results. The company is involved in the fields of Pharma, Nutrition, MedTech, and Biopharma.

Fresenius Kabi

Körber is an international technology group that focuses on transforming entrepreneurial thinking into customer success and shaping technological change. The company employs over 12,000 people at more than 100 locations worldwide.

Körber

biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

Formycon AG develops high-quality biosimilars, focusing on therapies in ophthalmology and immunology, among other significant chronic diseases. Their activities range from technical-pharmaceutical development to clinical studies and the preparation and submission of regulatory documents.

Metric
Company Name	Formycon AG	Fresenius Kabi	Körber	biosyn Arzneimittel GmbH
Symbol	FYB
MSH ID	COM:FORMYCON	COM:FRESENIUS-KABI	COM:KOERBER	DE:BIOSYN
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Technology	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Technology and Engineering	Pharmaceuticals
Country	DE	DE	DE	DE
Stage
Employee Count	238	10.00K
Website	formycon.com	fresenius-kabi.com	koerber.com	biosyn.de
LinkedIn			k%C3%B6rber	biosyn-arzneimittel-gmbh
Founders

Metric
Market Cap	1.02B
Enterprise Value
Monthly Web Traffic	6.53K	1.46K
Web Traffic Growth	0.44	0.82
Valuation
Raised Capital

Metric
Revenue	82.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit	24.62M
EBITDA	1.54M
Operating Income	-452.07K
Net Income	80.06M
EPS	5.03
Diluted EPS	4.99
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.36
Operating Profit Margin	-0.01
EBITDA Margin	0.02
Net Profit Margin	1.05
Return on Equity	0.16
Return on Assets	0.09
Return on Capital Employed	-0.00

COM:FORMYCON

Formycon AG

Last Close

46.85

25/11 09:20

Market Cap

965.83M

Beta: -

Volume Today

519

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	17.76
P/B Ratio	1.39
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	15.54
EV Multiple	689.86

Metric
Days Sales Outstanding	95.46
Days Payables Outstanding	2.81K
Days Inventory Outstanding	14.57
Operating Cycle	251.88
Cash Conversion Cycle	135.65
Asset Turnover	0.09

Metric
Operating Cash Flow	-9.93M
Free Cash Flow	-32.32M
Cash Flow to Debt	-0.32
Operating Cash Flow/Sales	-0.12
Free Cash Flow Yield	-0.06

Metric
Cash & Equivalents	28.56M
Accounts Receivable	-13.42M
Inventory	493.26K
Goodwill	47.04M
Debt to Capitalization	0.06
Debt to Assets
Current Ratio	0.46
Quick Ratio	2.06

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.40
SG&A to Revenue	0.27